Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Annals of Neurology

Volumn 67, Issue 4, 2010, Pages 452-461

  Bar Or, Amit ^a   Fawaz, Lama ^a   Fan, Boli ^a   Darlington, Peter J ^a   Rieger, Aja ^a   Ghorayeb, Christine ^a   Calabresi, Peter A ^b   Waubant, Emmanuelle ^c   Hauser, Stephen L ^c   Zhang, Jiameng ^d   Smith, Craig H ^d  

^a MCGILL UNIVERSITY   (Canada)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; LYMPHOTOXIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MITOGENS; MULTIPLE SCLEROSIS; MUROMONAB-CD3; PEPTIDES; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951757865     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21939     Document Type: Article

References (43)

1. Bar-Or A. The immunology of multiple sclerosis. In: Multiple sclerosis and other demyelinating disorders of the CNS. In: Lucchinetti C, ed. Semin Neurol 2008;28:5-21.
2. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400. (Pubitemid 351499869)
3. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688. (Pubitemid 351240747)
4. Cepok S, von Geldern G, Grummel V, et al. Accumulation of class switched IgD-IgM-memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol 2006;180:33-39. (Pubitemid 44692322)
5. Cross AH, Stark JL. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol Res 2005;32:85-97. (Pubitemid 41153616)
6. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008;98:121-149.
7. Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009;65:639-649.
8. Racke MK. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol 2008;21(suppl 1):S9-S18. (Pubitemid 351483538)
9. von Budingen HC, Harrer MD, Kuenzle S, et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008;38:2014-2023.
10. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180:63-70. (Pubitemid 44767709)
11. Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008;117:399-403. (Pubitemid 351643667)
12. Anderton SM, Fillatreau S. Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 2008;4:657-666.
13. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004; 172:3422-3427.
14. Evans JG, Chavez-Rueda KA, Eddaoudi A, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007;178:7868-7878. (Pubitemid 46898059)
15. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54.
16. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity 2008;28:18-28.
17. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007;178:6092-6099. (Pubitemid 46717389)
18. Rieger A, Bar-Or A. B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators. Nat Rev Immunol 2008;8:486-487. (Pubitemid 351733415)
19. Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008;8:391-397. (Pubitemid 351595221)
20. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810-816.
21. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-950. (Pubitemid 35154008)
22. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003;197:489-501. (Pubitemid 36278604)
23. Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16:219-230. (Pubitemid 34211962)
24. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008;64:187-199.
25. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 2008;180:800-808.
26. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008;28:799-809.
27. Herlands RA, Christensen SR, Sweet RA, et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008;29:249-260.
28. Uccellini MB, Busconi L, Green NM, et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha. J Immunol 2008;181:5875-5884.
29. Duda PW, Krieger JI, Schmied MC, et al. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 2000;165:7300-7307.
30. Fridkis-Hareli M, Santambrogio L, Stern JN, et al. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J Clin Invest 2002;109:1635-1643. (Pubitemid 34663526)
31. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004;172:7144-7153. (Pubitemid 38669158)
32. Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol 2008;180:4763-4773.
33. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652-659. (Pubitemid 44273613)
34. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006;19:80-94. (Pubitemid 43157648)
35. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005;4:195-202.
36. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001;108:1097-1104.
37. Cross AH, Piccio L, Klein RS, et al. B cell depletion in patients using rituximab (anti-CD20). Paper presented at: Keystone Symposium on Multiple Sclerosis; January 21-26, 2009; Santa Fe, NM.
38. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
39. Franciotta D, Salvetti M, Lolli F, et al. B cells and multiple sclerosis. Lancet Neurol 2008;7:852-858.
40. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-1189.
41. Peterson JW, Trapp BD. Neuropathobiology of multiple sclerosis. Neurol Clin 2005;23:107-129, vi-vii.
42. Wegner C, Stadelmann C. Gray matter pathology and multiple sclerosis. Curr Neurol Neurosci Rep 2009;9:399-404.
43. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581. (Pubitemid 38758544)